CANF Can-Fite Earnings per share for the last twelve months

CANF (Can-Fite BioPharma Ltd) - company brandmark

Can-Fite BioPharma focuses on adenosine receptors for the treatment of oncology and psoriasis, awaiting the commercialization of late-stage clinical trial results. The current earnings per share for the last 12 months are visualized below, where -6.34 forms the current metric value. The strategy is based on the A3AR agonist platform, aimed at creating safe oral agents for the specialized pharmaceutical market.

CANF (Can-Fite BioPharma) Net earnings per share for the last 12 months history from 07/04/2022 to 11/11/2026

Can-Fite BioPharma Ltd - analytical breakdowns and key metrics (CANF)

- current quotes and average value forecast:
Price Chart Can-Fite BioPharma|CANF - Average Forecast Price
- market capitalization data:
Market Value Can-Fite BioPharma Ltd.|CANF - Business Value
- shareholders' equity book value data:
Book Value per Share Can-Fite BioPharma|CANF - Company Net Assets|Market Value to Book Value Ratio canfite.com|CANF - Company Assets
- debt burden and liquidity indicators:
Debt to Equity Can-Fite BioPharma|CANF - Long-Term Debt to Equity|Short-Term Debt to Equity Can-Fite BioPharma, Ltd.|CANF - Company Cumulative Debt|Debts to Book Capitalization Can-Fite BioPharma Ltd.|CANF - Long-Term Indebtedness|Company Current Liabilities Can-Fite BioPharma|Quick Liquidity Indicator canfite.com
- net income and valuation multiples indicators:
CANF - Final Profit|Future Profit Can-Fite BioPharma|CANF - Market Price to Net Income Ratio|Forward P/E Multiple Can-Fite BioPharma Ltd.|CANF - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Can-Fite BioPharma Ltd.|CANF - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Can-Fite BioPharma|CANF - Earnings per share for the trailing year|Quarterly EPS earnings growth canfite.com|CANF - Earnings growth in current year|Net earnings per share growth forecast for next year Can-Fite BioPharma
Basic company analysis:Can-Fite BioPharma (CANF)
Mass-produced product of Can-Fite BioPharma, Ltd.

Operational efficiency is determined by the ability to generate real cash flow. This indicator is calculated by dividing the total annual net income by the total number of outstanding shares, reflecting the earnings per share. For Can-Fite BioPharma (CANF), this parameter confirms the monetization of exclusive patent developments in oncology. Growth in earnings per share indicates the commercial success of unique drugs. The trailing 12-month earnings per share trend captures these fundamental trends.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months hutch-med.com|Nuvation Bio (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (Monopar Pharma) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Inhibrx Corp (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics, Inc. HRTX|Nuvectis Pharma Inc. - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals, Inc.|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year beyondspringpharma.com BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology Holdings Inc. LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals)|CLRB (Cellectar Corp) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea Therapeutics Inc.)|Kazia - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (Silexion Therapeutics Corp)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Chimerix Inc (CMRX)|Earnings per share for the last twelve months Cyclacel Pharmaceuticals|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Therapeutics Inc (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech Corp) - Earnings per one share for the last 12 months